drugset
drugset / Trial / NCT06597760

A Clinical Study to Assess the Effect of Enlicitide on How the Body Processes Digoxin in Healthy Adult Participants (MK-0616-031)

NCT06597760 ↗

Phase 1 Completed 24 enrolled Merck Sharp & Dohme LLC Celerion · collab
RandomizedCrossoverOpen-labelBasic science

Summary

Researchers have designed a new study medicine called enlicitide decanoate as a new way to lower the amount of low-density lipoprotein cholesterol (LDL-C) in a person's blood. Enlicitide decanoate will be called "enlicitide" from this point forward. The purpose of this study is to learn the effect of this new study medicine enlicitide on digoxin (medicine used in heart disease) over time (a pharmacokinetic or PK study). Researchers will compare what happens to digoxin in the body over time when it is given with this new study medicine enlicitide in healthy adult participants.

Timeline

Start
2024-10-07
Primary completion
2024-11-01
Completion
2024-11-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Digoxin Other / unclassified 0.25 mg Oral
Subject Enlicitide Unknown 20 mg Oral

Indications

No indication recorded.